1. JAK/STAT Signaling
    Protein Tyrosine Kinase/RTK
  2. EGFR

AZ-5104 

Cat. No.: HY-B0793 Purity: 99.97%
Data Sheet SDS Handling Instructions

AZ-5104 is a potent EGFR inhibitor, displays potent antitumor activities both in vitro and in vivo.

For research use only. We do not sell to patients.
AZ-5104 Chemical Structure

AZ-5104 Chemical Structure

CAS No. : 1421373-98-9

Size Price Stock Quantity
10 mM * 1 mL in DMSO $55 In-stock
5 mg $50 In-stock
10 mg $90 In-stock
50 mg $320 In-stock
100 mg $520 In-stock
200 mg $720 In-stock
500 mg   Get quote  
1 g   Get quote  

* Please select Quantity before adding items.

Customer Review

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

Description

AZ-5104 is a potent EGFR inhibitor, displays potent antitumor activities both in vitro and in vivo. Target: EGFR AZ-5104 is an active, demethylated metabolite of AZD-9291. AZ-5104 displays similar overall activity profile with AZD-9291, but is more potent against mutant EGFR forms, while hitting the wild-type EGFR form at a lower concentration thus demonstrating a smaller selectivity margin compared with the parent.

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT02529995 AstraZeneca Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive August 24, 2015 Phase 1
NCT02197247 AstraZeneca Non Small Cell Lung Cancer December 4, 2014 Phase 1
NCT02161770 AstraZeneca Solid Tumours December 22, 2014 Phase 1
NCT02163733 AstraZeneca Advanced Non Small Cell Lung Cancer|Advanced (Inoperable) Non Small Cell Lung Cancer November 14, 2014 Phase 1
NCT02491944 AstraZeneca Oncology July 2015 Phase 1
NCT02224053 AstraZeneca Healthy Volunteer September 2014 Phase 1
NCT02317016 AstraZeneca Non Small Cell Lung Cancer March 10, 2015 Phase 1
NCT02157883 AstraZeneca Advanced Non Small Cell Lung Cancer|Advanced (Inoperable) Non Small Cell Lung Cancer November 6, 2014 Phase 1
NCT02096679 AstraZeneca Healthy Volunteers May 2014 Phase 1
NCT02923947 AstraZeneca|Quintiles, Inc. Solid Tumours May 4, 2017 Phase 1
NCT02908750 AstraZeneca|Quintiles, Inc. Non Small Cell Lung Cancer March 2, 2017 Phase 1
NCT02511106 AstraZeneca|Parexel Stage IB-IIIA Non-small Cell Lung Carcinoma October 21, 2015 Phase 3
NCT02296125 AstraZeneca|Parexel Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer December 3, 2014 Phase 3
View MoreCollapse
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 2.0594 mL 10.2970 mL 20.5939 mL
5 mM 0.4119 mL 2.0594 mL 4.1188 mL
10 mM 0.2059 mL 1.0297 mL 2.0594 mL
M.Wt

485.58

Formula

C₂₇H₃₁N₇O₂

CAS No.

1421373-98-9

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 28 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
AZ-5104
Cat. No.:
HY-B0793
Quantity: